- Conditions
- Overweight and Obesity
- Interventions
- Gelesis100 (2.25 g)
- Device
- Lead sponsor
- Gelesis, Inc.
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 11
- States / cities
- San Diego, California • Tustin, California • Aurora, Colorado + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ovarian Neoplasms
- Interventions
- Anetumab ravtansine (BAY94-9343), Pegylated Liposomal Doxorubicin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Oklahoma City, Oklahoma
- Conditions
- Atrial Fibrillation
- Interventions
- Left Atrial Appendage Device Implant
- Device
- Lead sponsor
- Heart Rhythm Clinical and Research Solutions, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 4 more
- Conditions
- Aging, Musculoskeletal Diseases, Osteoporosis
- Interventions
- 10 Weeks of Supervised Resistance Exercise Training, 10 Weeks of Supervised Endurance Exercise Training
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 60 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Recurrent Cutaneous Melanoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography, Surgical Procedure, VLP-encapsulated TLR9 Agonist CMP-001
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 187
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 134 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Integrated Care
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Fludarabine, Cytarabine, Gemtuzumab Ozogamicin, Azacitidine, Venetoclax
- Drug
- Lead sponsor
- PedAL BCU, LLC
- Other
- Eligibility
- 29 Days to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more
- Conditions
- Influenza
- Interventions
- oseltamivir (Tamiflu®)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 23 Months
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 24 more
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Lenalidomide
- Drug
- Lead sponsor
- European Myeloma Network B.V.
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Palifosfamide-Tris, doxorubicin, Placebo
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more
- Conditions
- Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, HZ/su vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 11
- States / cities
- Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 1,875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 404
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more
- Conditions
- Muscle Weakness
- Interventions
- LY2495655, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 75 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Gainesville, Georgia • Boston, Massachusetts + 4 more
- Conditions
- Alcohol Use Disorder
- Interventions
- Cannabidiol, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- management of therapy complications, psychosocial assessment and care
- Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
- Conditions
- Advanced Solid Tumor
- Interventions
- Erdafitinib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Colorado Springs, Colorado • Hollywood, Florida + 22 more
- Conditions
- Lung Carcinoma
- Interventions
- Biopsy, Biospecimen Collection, Bronchoscopy, Extended Release Metformin Hydrochloride, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Buffalo, New York
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
- Interventions
- ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
- Device · Drug
- Lead sponsor
- Inari Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
- Conditions
- Lung Cancer
- Interventions
- monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody GD2 anti-idiotype vaccine, cisplatin, etoposide, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 99
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Cancer
- Interventions
- Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 6 Months to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • St. Petersburg, Florida • Atlanta, Georgia + 1 more
- Conditions
- Pancreatic Neoplasms
- Interventions
- BAY86-9766+Gemcitabine
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Pittsfield, Massachusetts
- Conditions
- Hypoglycemia
- Interventions
- XOMA 358 single dose level A, XOMA 358 single dose level B, XOMA 358 single dose level C, XOMA 358 multiple dose level 1
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Diabetes Mellitus, Type 2, Impaired Renal Function
- Interventions
- Dapagliflozin 10 MG [Farxiga]
- Drug
- Lead sponsor
- Emerald Clinical Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, cisplatin, docetaxel, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 160
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more